Schizophrenia Mental and Behavioural Disorders
Conditions
Interventions
This randomized, double-blind, placebo-controlled trial will compare arachidonic acid (AA) supplementation versus placebo in schizophrenia patients. Eligible participants will be randomly allocated 1
Sponsors
Shanghai Jiao Tong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Confirmed diagnosis of schizophrenia according to ICD-10 criteria 2. Willingness to participate, with signed informed consent from the patient or their legal guardian
Exclusion criteria
Exclusion criteria: 1.Patients should not have a history of other mental disorders, neurological disorders, serious physical diseases, traumatic brain injury, substance abuse, or dependence 2. Enrollment in another clinical trial within 4 weeks prior to screening 3. Pregnancy, lactation, or plans to conceive during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function will be measured using the Cambridge Neuropsychological Test Automated Battery® (CANTAB®) system at baseline, week 3, and 6. | — |
Secondary
| Measure | Time frame |
|---|---|
| RBC's fatty acids will be measured using gas chromatography-mass spectrometry at baseline and week 6. | — |
Countries
China
Contacts
Public ContactYan Gao
Outcome results
None listed